Shell Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $145K | Sell |
3,026
-4,585
| -60% | -$185K | 0.01% | 557 |
|
|
2025
Q2 | $240K | Sell |
7,611
-1,440
| -16% | -$46.1K | 0.01% | 708 |
|
|
2025
Q1 | $296K | Sell |
9,051
-291
| -3% | -$10.3K | 0.01% | 622 |
|
|
2024
Q4 | $338K | Hold |
9,342
| – | – | 0.01% | 625 |
|
|
2024
Q3 | $291K | Buy |
+9,342
| New | +$292K | 0.01% | 703 |
|
|
2024
Q1 | $264K | Sell |
9,876
-990
| -9% | -$29.5K | 0.01% | 723 |
|
|
2023
Q4 | $314K | Sell |
10,866
-3,281
| -23% | -$87K | 0.01% | 698 |
|
|
2023
Q3 | $390K | Sell |
14,147
-244
| -2% | -$7.43K | 0.02% | 662 |
|
|
2023
Q2 | $433K | Sell |
14,391
-81
| -0.6% | -$2.83K | 0.02% | 635 |
|
|
2023
Q1 | $524K | Sell |
14,472
-50
| -0.3% | -$1.92K | 0.02% | 538 |
|
|
2022
Q4 | $518K | Sell |
14,522
-3,104
| -18% | -$108K | 0.02% | 521 |
|
|
2022
Q3 | $597K | Sell |
17,626
-4,606
| -21% | -$150K | 0.02% | 495 |
|
|
2022
Q2 | $643K | Buy |
22,232
+45
| +0.2% | +$1.29K | 0.02% | 575 |
|
|
2022
Q1 | $717K | Sell |
22,187
-3,281
| -13% | -$101K | 0.02% | 633 |
|
|
2021
Q4 | $743K | Buy |
25,468
+108
| +0.4% | +$3.28K | 0.02% | 717 |
|
|
2021
Q3 | $676K | Sell |
25,360
-1,090
| -4% | -$29.3K | 0.02% | 714 |
|
|
2021
Q2 | $814K | Buy |
26,450
+1,430
| +6% | +$43.8K | 0.02% | 669 |
|
|
2021
Q1 | $655K | Buy |
25,020
+4,773
| +24% | +$133K | 0.01% | 734 |
|
|
2020
Q4 | $509K | Hold |
20,247
| – | – | 0.01% | 793 |
|
|
2020
Q3 | $422K | Buy |
20,247
+5,148
| +34% | +$117K | 0.01% | 755 |
|
|
2020
Q2 | $359K | Buy |
+15,099
| New | +$334K | 0.01% | 815 |
|
|
2019
Q3 | – | Sell |
-30,436
| Closed | -$1.01M | – | 1264 |
|
|
2019
Q2 | $1.01M | Sell |
30,436
-691
| -2% | -$23.7K | 0.02% | 556 |
|
|
2019
Q1 | $1.09M | Hold |
31,127
| – | – | 0.02% | 527 |
|
|
2018
Q4 | $1.03M | Sell |
31,127
-2,600
| -8% | -$112K | 0.03% | 502 |
|
|
2018
Q3 | $1.7M | Sell |
33,727
-13,465
| -29% | -$665K | 0.03% | 436 |
|
|
2018
Q2 | $2.82M | Sell |
47,192
-2,567
| -5% | -$133K | 0.06% | 339 |
|
|
2018
Q1 | $2.28M | Hold |
49,759
| – | – | 0.05% | 370 |
|
|
2017
Q4 | $1.98M | Hold |
49,759
| – | – | 0.04% | 401 |
|
|
2017
Q3 | $1.99M | Sell |
49,759
-1,100
| -2% | -$47.6K | 0.04% | 374 |
|
|
2017
Q2 | $2.19M | Hold |
50,859
| – | – | 0.05% | 364 |
|
|
2017
Q1 | $1.59M | Sell |
50,859
-3,559
| -7% | -$95.4K | 0.04% | 440 |
|
|
2016
Q4 | $1.37M | Sell |
54,418
-475
| -0.9% | -$10.6K | 0.03% | 518 |
|
|
2016
Q3 | $1.36M | Sell |
54,893
-2,518
| -4% | -$57K | 0.03% | 536 |
|
|
2016
Q2 | $1.17M | Buy |
+57,411
| New | +$1.02M | 0.03% | 530 |
|
Other funds holding SUPN
AC
Shell Asset Management's SUPN Position: Q3 2025 in Review
Shell Asset Management reduced its Supernus Pharmaceuticals (SUPN) stake by 60% in Q3 2025, selling an estimated $185K and leaving 3,026 shares worth $145K. The position accounts for 0.01% of the portfolio, ranked #557.
Shell Asset Management first reported a position in SUPN in Q2 2016 and has held it in 34 quarters since. The position peaked at $2.82M in Q2 2018. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.
- Shell Asset Management held 3,026 shares of Supernus Pharmaceuticals worth $145K as of Q3 2025.
- Shell Asset Management sold 4,585 Supernus Pharmaceuticals shares in Q3 2025, an estimated $185K.
- Supernus Pharmaceuticals made up 0.01% of Shell Asset Management's portfolio in Q3 2025, its #557 holding.
- Shell Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2016 and has held it in 34 quarters since.
- Shell Asset Management's Supernus Pharmaceuticals position peaked at $2.82M in Q2 2018.
- 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.
Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.